Pharmaceutical - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

101 to 125 of 317 results

KaloBios tanks as it halts KB003 development for asthma

31-01-2014

USA-based KaloBios Pharmaceuticals revealed disappointing top line results from a Phase II study on KB003…

KaloBios PharmaceuticalsKB003PharmaceuticalResearchRespiratory and Pulmonary

Sanofi and MAbImprove LabEx collaborate on rare lung disease

Sanofi and MAbImprove LabEx collaborate on rare lung disease

24-01-2014

French drug major Sanofi and MAbImprove Laboratoire d'Excellence (LabEx), coordinated by France’s Universite…

PharmaceuticalRare diseasesResearchRespiratory and PulmonarySanofi

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

24-01-2014

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given…

Cardio-vascularEuropeNovartisPharmaceuticalRegulationRespiratory and PulmonaryXolair

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Japanese approval for Bayer’s riociguat for CTEPH

Japanese approval for Bayer’s riociguat for CTEPH

20-01-2014

German pharma major Bayer has received approval from the Ministry of Health, Labor and Welfare for riociguat,…

AdempasAsia-PacificBayerPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

Study shows Fostair has comparable efficacy to Seretide in asthma patients

Study shows Fostair has comparable efficacy to Seretide in asthma patients

20-01-2014

A study has shown that asthma patients may be switched from Seretide to Fostair at an equivalent or lower…

Chiesi FarmaceuticiFostairGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretideUK

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

08-01-2014

UK pharma giant GlaxoSmithKline and US partner Theravance today announced the launch of Relvar Ellipta…

GlaxoSmithKlineMarkets & MarketingNorthern EuropePharmaceuticalRelvar ElliptaRespiratory and PulmonaryTheravanceUK

Ikaria sells commercial business to Madison Dearborn for $1.6 billion

03-01-2014

US critical care company Ikaria says that its investor group and employee shareholders have reached a…

IkariaInomaxMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

19-12-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has received Danish marketing authorization…

DenmarkPharmaceuticalRegulationRespiratory and PulmonarySandozVectura

US FDA approves GSK/Theravance’s Anoro Ellipta for COPD

US FDA approves GSK/Theravance’s Anoro Ellipta for COPD

19-12-2013

The US Food and Drug Administration late yesterday approved Anoro Ellipta (umeclidinium and vilanterol…

Anoro ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravance

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

New agreement with GSK provides new medicines, saves millions for New Zealand

New agreement with GSK provides new medicines, saves millions for New Zealand

11-12-2013

A new agreement with the local subsidiary of UK pharma giant GlaxoSmithKline by New Zealand’s Pharmaceutical…

Anti-viralsAsia-PacificGlaxoSmithKlineHealthcareHematologyNew ZealandPharmaceuticalPricingRespiratory and PulmonarySeretideSerevent Diskus

New UK pharma company to target respiratory disease

New UK pharma company to target respiratory disease

11-12-2013

A new biopharmaceutical company has been founded to develop innovative new approaches to treat respiratory…

FinancialPharmaceuticalRespiratory and PulmonaryUK

GNI Group out-licenses Etuary to AFT Pharma

10-12-2013

Japan headquartered GNI Group, a clinical-stage bio-pharmaceutical company focusing on major diseases…

Asia-PacificLicensingPharmaceuticalRespiratory and Pulmonary

Bayer CEO calls for greater appreciation of innovation

Bayer CEO calls for greater appreciation of innovation

19-11-2013

Advances in cancer therapy are expected in the next years, thanks in particular to treatment using antibody-drug…

BayerNephrology and HepatologyOncologyPharmaceuticalResearchRespiratory and Pulmonary

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

19-11-2013

UK drug delivery specialist Skyepharma (LSE: SKP) has announced that Flutiform has been launched in Japan…

Asia-PacificFlutiformKyorin PharmaceuticalsLicensingPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Vectura posts flat sales and increased loss for first-half 2013

19-11-2013

UK-based developer of inhaled therapies Vectura Group has announced its unaudited interim results for…

FinancialNovartisPharmaceuticalRespiratory and PulmonaryVectura

Relvar Ellipta approved for asthma and COPD in Europe

Relvar Ellipta approved for asthma and COPD in Europe

19-11-2013

The European Commission has granted marketing authorization for Relvar Ellipta (fluticasone furoate/vilanterol…

EuropeGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

Numab reacquires advanced asthma compound from Sucampo

13-11-2013

Privately-held Switzerland-based Numab AG, a company focused on the discovery and development of innovative…

ND003NumabPharmaceuticalRespiratory and PulmonarySucampo

Boehringer Ingelheim files for expanded EU indication for Respimat

Boehringer Ingelheim files for expanded EU indication for Respimat

13-11-2013

German independent drug major Boehringer Ingelheim has submitted an applications to extend the indication…

Boehringer IngelheimEuropePharmaceuticalRegulationRespimatRespiratory and PulmonarySpiriva

GA and PhRMA partner on pilot scheme to enhance patient engagement in three therapy areas

05-11-2013

The USA’s Genetic Alliance and the Pharmaceutical Research and Manufacturers of America have announced…

Gastro-intestinalsHealthcareHematologyNorth AmericaPharmaceuticalRespiratory and Pulmonary

Actelion says PAH drug Opsumit now available in USA

Actelion says PAH drug Opsumit now available in USA

05-11-2013

Actelion has confirmed that Opsumit 10mg, an oral, dual endothelin receptor antagonist for pulmonary…

ActelionMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonary

Aclidinium and formoterol fixed dose combo for COPD filed in Europe by Almirall

04-11-2013

Spain’s largest drugmaker Almirall has filed a Marketing Authorization Application to the European…

aclidiniumAlmirallEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Theravance and GSK launch Breo Ellipta in USA

Theravance and GSK launch Breo Ellipta in USA

30-10-2013

GlaxoSmithKline and US partner Theravance today announced that Breo Ellipta for COPD is available to…

Breo ElliptaFinancialGlaxoSmithKlineMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and PulmonaryTheravance

101 to 125 of 317 results

Parexel

Parexel

Back to top